<?xml version="1.0" encoding="UTF-8"?>
<p id="par0105">There were no significant differences (
 <italic>P &lt; 0.05</italic>) in plasma ALT activities of 
 <italic>Wistar</italic> rats administered respective doses of AESG, when compared with the plasma ALT activity of the control (
 <xref rid="fig0020" ref-type="fig">Fig. 4</xref>). The plasma AST activities of test rats administered AESG 500 and 1000 mg/kg, respectively, was not significantly different (
 <italic>P &lt; 0.05</italic>), although rats administered 2000 mg/kg recorded significant reduction (
 <italic>P &lt; 0.05</italic>) in plasma AST activity relative to the plasma AST activity of the control (
 <xref rid="fig0020" ref-type="fig">Fig. 4</xref>). Plasma ALP activities were significantly elevated (
 <italic>P &lt; 0.05</italic>) in all groups of experimental rats given AESG; the highest ALP activity was recorded in the group of rats administered AESG 500 and 1000 mg/kg, respectively, relative to the control (
 <xref rid="fig0020" ref-type="fig">Fig. 4</xref>). The plasma GGT activity of experimental rats administered respective doses of AESG was significantly lowered (
 <italic>P &lt; 0.05</italic>) compared to the control (
 <xref rid="fig0020" ref-type="fig">Fig. 4</xref>). Plasma total protein and albumin concentration of rats administered respective doses of AESG was not significantly different (
 <italic>P &lt; 0.05</italic>) when compared to their respective controls (
 <xref rid="fig0025" ref-type="fig">Fig. 5</xref>).
</p>
